Home » BI Shutters Ben Venue in the Face of Remediation Price Tag
BI Shutters Ben Venue in the Face of Remediation Price Tag
Boehringer Ingelheim (BI) has decided to close Ben Venue Laboratories, its beleaguered generic injectable drugmaking unit, by the end of the year, saying the subsidiary’s remediation efforts will total about $1 billion and are not worth the cost of keeping it open. The decision will also affect Bedford Laboratories, which markets injectable drugs made by Ben Venue. Bedford will continue to market Ben Venue’s portfolio of available products, including those it manufactured prior to ceasing production, BI told DID Friday.
Drug Industry Daily
Drug Industry Daily
Upcoming Events
-
02May
-
07May
-
14May
-
23May
-
30May